Related Experiment Video
Updated: Jun 9, 2026
10:29
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Structure based design of 11β-HSD1 inhibitors
1Vitae Pharmaceuticals, 502 W. Office Center Drive, Fort Washington, PA 19034, USA. ssingh@vitaerx.com
Current Pharmaceutical Biotechnology
|September 3, 2010
Summary
Targeting cortisol with 11β-HSD1 inhibitors offers a new strategy for metabolic syndrome. Structure-based design using enzyme crystal structures guides the development of diverse drug candidates.
Area of Science:
- Medicinal Chemistry
- Enzyme Inhibition
- Metabolic Disorders
Background:
- Elevated tissue-specific cortisol contributes to metabolic syndrome.
- 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is a key regulator of cortisol.
- Inhibiting 11β-HSD1 presents a potential therapeutic avenue for metabolic syndrome.
Purpose of the Study:
- To summarize structure-activity relationships and binding modes of 11β-HSD1 inhibitors.
- To present pharmacodynamic data for various classes of 11β-HSD1 inhibitors.
- To highlight the role of structure-based design in developing novel therapeutics.
Main Methods:
- Utilizing high-resolution X-ray crystal structures of enzyme-inhibitor complexes.
- Analyzing structure-activity relationships across diverse inhibitor classes.
- Summarizing pharmacodynamic data from preclinical studies.
Main Results:
- Diverse classes of 11β-HSD1 inhibitors have been designed.
- Specific binding modes and structure-activity trends were identified.
- Pharmacodynamic profiles of inhibitors were evaluated.
Conclusions:
- 11β-HSD1 inhibitors are promising for metabolic syndrome treatment.
- Structure-based design is effective for developing potent inhibitors.
- Further development of these inhibitors warrants investigation.
More Related Videos
Related Concept Videos
01:28Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:30Enzyme Inhibition
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...